PPBT Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States...

Stats
Dagens volum	172 012
Gjennomsnittsvolum	146 376
Markedsverdi	14.55M
EPS	$0 ( 2024-03-06 )
Neste inntjeningsdato	( $-0.150 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.540
ATR14	$0.00800 (1.63%)

Volum Korrelasjon

Lang: -0.07 (neutral)

Kort: 0.00 (neutral)

Signal:(48.387) Neutral

Purple Biotech Ltd. Korrelasjon

10 Mest positive korrelasjoner
HALL	0.893
SNCR	0.877
NEXT	0.864
LMNL	0.855
MTEK	0.833
WTFC	0.817
TSLA	0.809
SQFTP	0.801

10 Mest negative korrelasjoner
BNIXU	-0.942
BLZE	-0.872
ARTNA	-0.868
DOYU	-0.863
ACST	-0.852
FNKO	-0.844
ANZU	-0.841
CAMP	-0.832
CXSE	-0.831
WTBA	-0.829

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Purple Biotech Ltd. Korrelasjon - Valuta/Råvare

-0.01
( neutral )

0.00
( neutral )

-0.21
( neutral )

Purple Biotech Ltd. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-199 000 (0.00 %)
EPS:	$-0.810

FY	2023
Omsetning:	$0
Bruttogevinst:	$-199 000 (0.00 %)
EPS:	$-0.810

FY	2022
Omsetning:	$-910 000
Bruttogevinst:	$-1.11M (122.09 %)
EPS:	$-1.130

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.050

Financial Reports:

No articles found.

Purple Biotech Ltd.

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.